1. An automated platform-as-a-service provisioning system, comprising:
a system deployment module operatively configured to receive specifications for and direct the creation of a computing platform;
an operations orchestration module operatively configured to guide the workflow of component modules and sub-systems to carry out provisioning of a platform;
an automation center module operatively configured to create and tune virtual machine components of a platform based on received specifications;
an automation platform operatively configured to install software and configuration details on the created machine based on instructions stored in memory;
a repository module containing all artifacts related to a platform and accessible by the automation platform.
2. The automated platform-as-a-service provisioning system of claim 1 where the system further comprises a configurations and applications management module; and
a build tool operatively configured to transform configuration details and applications into files that are accessible to and readable by the automation platform.
3. A method for fast provisioning of a platform-as-a-service, comprising:
receiving a specification for a platform;
creating an infrastructure template of the platform based on the requested platform specification;
creating a platform model by installing applications and configuration details;
replicating the platform model to meet capacity and location requirements;
registering the location with the data center and network details required to identify the platform.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for preparing a radiolabeled nucleoside analogue, comprising:
(a) preparing a labeling precursor comprising a 5-tributylstannyl-2\u2032-pyrimidine derivative, wherein the pyrimidine derivative in the labeling precursor is selected from a group consisting of a cytidine, a thymidine, a uridine, and a derivative thereof;
(b) iododestannylating the labeling precursor with a radionuclide under an oxidation condition to obtain a radioactive iodine labeled crude product, wherein the radioactive iodine comprises a 123I and a 131I; and
(c) purifying the radioactive iodine labeled crude product by directly cooling and solidifying with a liquid nitrogen in a vacuum system provided with an active carbon adsorbent so as to obtain the radiolabeled nucleoside analogue as a freezing dried powder merely containing a 123131IICdR and a trace CdR.
2. The preparation method according to claim 1, wherein the pyrimidine derivative in Step (a) is one of the cytidine and the thymidine.
3. The preparation method according to claim 1, wherein the labeling precursor in Step (a) is a pyrimidine derivative including a 1-(2-deoxy-\u03b2-D-arabinofuranosyl)-5-tributylstannyl.
4. The preparation method according to claim 1, wherein the oxidation condition in Step (b) is an oxidation with a hydrogen peroxide.
5. The preparation method according to claim 1, wherein the purification in Step (c) is performed on a silica gel column.